We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Kali Inc (CE) | USOTC:KALY | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
Dallas, TX -- January 29, 2020 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today announced plans to further pursue the prevailing cannabis consolidation market opportunity by acquiring smaller cannabis infusion companies. Multiple cannabis investment market analysts have forecasted a market wide consolidation as larger cannabis sector firms acquire smaller firm. PURA has built expertise and resources to infuse cannabis into beverages and is now looking to expand the capacity to include food infusion capacity. PURA is currently exploring the acquisition of Kali-Extracts’ (USOTC: KALY) CBD confections business. PURA management now confirms that the company is also exploring additional acquisition opportunities. PURA currently produces the leading CBD beverage in the sports nutrition market, EVERx CBD Sports Water. EVERx now has distribution in Europe, Latin America and Africa in addition to within the United States. PURA management believes the company is well staged for acquiring and growing additional cannabis infused beverages and foods.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
1 Year Kali (CE) Chart |
1 Month Kali (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
